Tipifarnib
- Generic Name
- Tipifarnib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H22Cl2N4O
- CAS Number
- 192185-72-1
- Unique Ingredient Identifier
- MAT637500A
- Background
Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.
- Indication
Investigated for use/treatment in colorectal cancer, leukemia (myeloid), pancreatic cancer, and solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00052728
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸NCI - Center for Cancer Research, Bethesda, Maryland, United States
Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 62
- Registration Number
- NCT00049114
- Locations
- 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States
Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00047190
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
R115777 Plus Topotecan in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-11-09
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT00005990
- Locations
- 🇺🇸
NYU Cancer Institute at New York University Medical Center, New York, New York, United States
Tipifarnib in Treating Young Patients With Refractory Leukemia
- Conditions
- Locations
- 🇺🇸
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus, Atlanta, Georgia, United States
🇺🇸Floating Hospital for Children, Boston, Massachusetts, United States
🇦🇺Princess Margaret Hospital for Children, Perth, Western Australia, Australia
A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS)
- Conditions
- Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)de Novo Myelodysplastic SyndromesSecondary Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 44
- Registration Number
- NCT00045396
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 154
- Registration Number
- NCT00026104
- Locations
- 🇺🇸
Radiation Therapy Oncology Group, Philadelphia, Pennsylvania, United States
Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 12
- Registration Number
- NCT00025480
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-06-26
- Target Recruit Count
- 136
- Registration Number
- NCT00005859
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸UCSF Comprehensive Cancer Center, San Francisco, California, United States
R115777 in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-02-08
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT00025454
- Locations
- 🇺🇸
City of Hope Medical Group, Pasadena, California, United States
🇺🇸University of California Davis Cancer Center, Sacramento, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.